VERAgene is the only non-invasive prenatal test that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate to severe phenotype with significant impact on the quality of life. By combining detection of aneuploidies and microdeletions with the screening of monogenic diseases, VERAgene provides a comprehensive solution to prospective parents.

WHAT SHOULD I ASK MY DOCTOR?

WHAT IS A NON-INVASIVE PRENATAL TEST (NIPT)?

It is a test that a pregnant woman can take to check for genetic conditions of the fetus before birth.

WHAT ARE GENETIC CONDITIONS?

Genetic conditions are caused by unwanted changes in the genome that happen during conception. Three types of genetic conditions are detected with the test:

  • aneuploidies are genetic conditions that occur when a chromosome has an extra copy (trisomy) or is missing a copy (monosomy)
  • microdeletions are genetic conditions caused by a small deletion in a specific region of a chromosome
  • single gene diseases are genetic conditions caused by mutations in a gene

How does it work?

During pregnancy, fetal cell-free DNA travels from placenta and circulates in the mother’s blood along with her own cell-free DNA. Cell-free DNA is isolated from the mother’s blood, and analysed with the father’s DNA sample to detect any potential genetic mutations using proprietary new generation technology and bioinformatics. The results of the screening test are then sent to the doctor who communicates them to the family with the appropriate counseling.

WHAT CONDITIONS CAN BE DETECTED?

VERAgene can detect trisomies of chromosomes 21, 18, 13, aneuploidies of X and Y chromosomes, DiGeorge syndrome, 1p36 deletion syndrome, Smith-Magenis syndrome and Wolf-Hirschhorn syndrome, and 100 monogenic diseases. VERAgene targets over 2,000 mutations to screen for 100 monogenic diseases. By combining detection of aneuploidies and microdeletions with the screening of monogenic diseases, VERAgene provides a comprehensive picture of the pregnancy using a single test.

AUTOSOMAL ANEUPLOIDIES

  • Down syndrome (Trisomy 21)
  • Edwards syndrome (Trisomy 18)
  • Patau syndrome (Trisomy 13)

SEX CHROMOSOME ANEUPLOIDIES

  • Turner syndrome (Monosomy X)
  • Triple X syndrome (Trisomy X)
  • Klinefelter syndrome (XXY)
  • Jacobs syndrome (XYY)
  • XXYY syndrome

MICRODELETIONS

  • DiGeorge syndrome (22q11.2)
  • 1p36 deletion syndrome
  • Smith-Magenis syndrome (17p11.2)
  • Wolf-Hirschhorn syndrome (4p16.3)

Monogenic Diseases

IS THERE AN AGE LIMIT FOR VERAgene?

No. VERAgene can be done by pregnant women of all ages because it screens for genetic conditions that don’t have any maternal age-associated risk.

WHEN CAN I DO THE TEST?

VERAgene test can be done as early as the 10th week of gestation.

WHY SHOULD A PREGNANT WOMAN DO THE VERAgene TEST?

Microdeletions and single gene diseases – unlike aneuploidies – do not have a maternal age-associated risk, and most of them do not have chemical or ultrasound biomarkers that can help in early detection. The cumulative risk for the fetus to be affected by one of the genetic conditions screened by VERAgene is 1 in 50 in moderate to high risk pregnancies and could be higher in some ethnic populations where some of the conditions are more prevalent. VERAgene can accurately screen for these conditions to help parents take informed decisions about possible treatments and clinical management.

HOW CAN I TAKE THE VERAgene TEST?

  • BE AT LEAST 10 WEEKS PREGNANT
  • ASK YOUR DOCTOR ABOUT TAKING VERAgene
  • YOUR DOCTOR WILL COLLECT A BLOOD SAMPLE FROM YOU AND A BUCCAL SWAB FROM THE FATHER
  • THE SAMPLES WILL BE ANALYSED IN OUR LABORATORIES
  • THE TEST RESULTS WILL BE SENT TO YOUR DOCTOR IN 4-7 WORKING DAYS

FAQ

  • What is NIPT?

    NIPT is a screening test taken by a pregnant woman to check for genetic conditions of the fetus before birth. NIPT analyzes cell-free DNA in the mother’s blood to identify these genetic conditions. NIPT is important because it provides a safe and accurate way to test the baby before birth for genetic disorders, the most common of which is Down syndrome. Before the introduction of this revolutionary test, the options to test for Down syndrome were either screening methods like ultrasound combined with biochemical testing which have low accuracy (approximately 80-95%) or high accuracy prenatal diagnosis that uses invasive methods [e.g. amniocentesis or chorionic villi sampling (CVS)] which have 0.5% risk for miscarriage.

  • What are genetic conditions?

    The human genome is sorted into twenty-three pairs of chromosomes. Genetic conditions are caused by unwanted changes in the genome that happen during conception. There are three types of genetic conditions:

    • aneuploidies are genetic conditions that occur when a chromosome has an extra copy (trisomy) or is missing a copy (monosomy)
    • microdeletions are genetic conditions caused by the deletion of part of a chromosome
    • single gene diseases are genetic conditions caused by pathogenic alterations (mutations) in a gene

  • What is VERAgene comprehensive NIPT?

    VERAgene is the only non-invasive prenatal test that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate to severe phenotype with significant impact on the quality of life. These genetic diseases exhibit symptoms such as congenital anomalies, development delays, hearing loss, blindness, metabolic diseases, etc.

  • What genetic conditions can be detected by VERAgene?

    VERAgene can screen for trisomies such as Down syndrome, Edwards syndrome, Patau syndrome, sex chromosome aneuploidies, microdeletions such as DiGeorge syndrome, 1p36 deletion syndrome, Smith-Magenis syndrome and Wolf-Hirschhorn syndrome and 100 monogenic diseases with autosomal recessive and X-linked inheritance. These include Beta Thalassemia, Cystic Fibrosis, Tay-Sachs disease, Canavan disease, Sickle Cell disease, Phenylketonuria, Alport syndrome and many more. By combining detection of aneuploidies and microdeletions with the screening of monogenic diseases, VERAgene provides a comprehensive picture of the pregnancy using a single test.

  • What are Down syndrome, Edwards syndrome and Patau syndrome?

    Down syndrome, Edwards syndrome and Patau syndrome are genetic disorders caused by chromosomal trisomies. Down syndrome is caused by an extra copy of chromosome 21 whereas Edwards syndrome and Patau syndrome are caused by an extra copy of chromosome 18 and chromosome 13, respectively. Down syndrome is characterized by intellectual impairment and congenital abnormalities. Down syndrome occurs approximately in 1 in 700 pregnancies but is more frequent in pregnancies in women over 35. Edwards syndrome and Patau syndrome are less common occurring in 1 in 3000 and 1 in 10000 pregnancies, respectively. Edwards and Patau syndromes are characterized by severe congenital abnormalities and rarely survive past the first year of life.

  • What are sex chromosome aneuploidies?

    Sex chromosome aneuploidies are genetic disorders caused by the presence or absence of a sex chromosome. The 23rd pair of chromosomes determine the sex of an individual. Women have two X chromosomes and men have one X and one Y chromosome. There are four major sex chromosome aneuploidies:

    • Turner syndrome is characterized by the presence of a single X chromosome.
    • Triple X syndrome is characterized by the presence of three X chromosomes.
    • Klinefelter syndrome is characterized by the presence of two X chromosomes and one Y chromosome.
    • Jacob syndrome is characterized by the presence of one X chromosome and two Y chromosomes.

  • What are microdeletions?

    Microdeletions are genetic conditions caused by the loss of a part of a chromosome. Microdeletions are characterized by congenital abnormalities and intellectual impairment. The severity of the symptoms varies depending on the size and location of the microdeletion. The most common microdeletion syndrome is DiGeorge syndrome which occurs approximately once in 1000 pregnancies. The prevalence of DiGeorge syndrome increases to 1 in 100 in pregnancies with major structural anomalies such as congenital heart disease.

  • What are monogenic diseases?

    Monogenic diseases are caused by a variant (a version that is different from the standard) in a single gene (single gene diseases). Such conditions can be autosomal dominant which are caused when a variant exists on only one chromosome, or autosomal recessive where a variant needs to be present in both chromosomes. There are also X-linked diseases, where the mutation is always on the X chromosome and affects males and females differently. VERAgene analyses over 2000 variants to detect 100 autosomal recessive and X-linked monogenic diseases.

  • What are autosomal diseases?

    Autosomal diseases are conditions that affect chromosome pairs 1 to 22, the ‘autosomal’ chromosomes. These genetic conditions can either be autosomal dominant or autosomal recessive.

  • What are X-linked diseases?

    X-linked diseases are those that affect the X chromosome on the 23rd chromosome pair, which determines gender. Generally, they are not as severe as autosomal diseases, but they may affect quality of life as common symptoms include fertility problems and cognitive difficulties. X-linked diseases are most often passed from affected or carrier mothers to their sons, as fathers pass the Y chromosome on all their male offspring.

  • Why do X-linked diseases affect males and females differently?

    As males have one X and one Y chromosome, when their X chromosome has a mutation the disease always manifests. Females have two X chromosomes, and when one of their X chromosomes has a mutation they are carriers of an X-linked disease. They may exhibit some symptoms of the disease or no symptoms at all, due to ‘X-inactivation’ – a mechanism that always ‘shuts off’ one of the two X chromosomes in females so they don’t have twice the number of genes as males which would be toxic. As this process is random in the female cells, the X chromosome with the mutation can be silenced in varying degree in female carriers; thus explaining the symptom variability shown.

  • Why should expecting parents consider VERAgene?

    Microdeletions and single gene diseases – unlike aneuploidies – do not have a maternal age associated risk, and most of them do not have chemical or ultrasound biomarkers that can help in early detection. The cumulative risk for the fetus to have either an aneuploidy, microdeletion or a monogenic condition screened by VERAgene is 1 in 50 in moderate to high-risk pregnancies. VERAgene can accurately screen for these conditions to help parents take informed decisions about possible treatment and clinical management.

  • I have other questions. Where can I find additional information?

    Please contact your doctor or healthcare provider for additional information.

Other Products

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!